Insulin analogs (multiple)Group of peptide hormone medicines
Insulin analogues are engineered versions of insulin with altered timing of action. This is a family of medicines, not one compound: rapid mealtime coverage and longer background coverage serve different purposes.
Before comparing this entry. This record represents a group. Individual medicines need separate indication, product and country checks.
What is Insulin analogs (multiple)?
Insulin analogues are engineered insulin medicines with different durations of action. Rapid-acting examples include lispro, aspart and glulisine; longer-acting basal examples include glargine and degludec.
How it works
They retain insulin-receptor activity while changes to the preparation alter how quickly insulin becomes available and how long it acts. Mealtime and basal preparations address different parts of glucose regulation.
Effects studied
Glucose control and hypoglycaemia
Comparisons can examine HbA1c and patterns of low glucose, including overnight episodes. Similar average glucose control can coexist with different hypoglycaemia profiles.
Evidence: Product-specific comparative diabetes evidence. 2
What does the evidence show?
Extensive product-specific diabetes evidence
The same receptor, a different time course
Insulin helps regulate glucose use and storage. Analogue design changes how quickly a preparation becomes available and how long it acts, while retaining activity at the insulin receptor. The timing of action is central to what each preparation is used for.
Meals and background needs
Rapid-acting analogues include lispro, aspart and glulisine. Longer-acting basal examples include glargine and degludec. Basal treatment addresses background insulin needs, while mealtime treatment is matched to another part of glucose regulation. Regular human insulin and NPH are insulin preparations too, but are not modified insulin analogues in the same sense.
What comparison trials measure
Trials may examine HbA1c, time in glucose range, nocturnal hypoglycaemia or severe hypoglycaemia. Similar average glucose control can coexist with different patterns of low glucose. Comparisons need to specify the outcome and population before describing one insulin as better.
Safety is product-specific and immediate
Hypoglycaemia is a central risk and can be severe. Concentration, pen or pump compatibility, meal timing, illness and other medicines all affect treatment. This grouped introduction explains the roles; it does not offer conversion instructions. Individual product pages and professional guidance are needed for any change, because a small naming or formulation error can have a large clinical effect.
Safety & status
Hypoglycaemia can be severe. Concentration, delivery device, meal timing, illness and other medicines affect treatment; product changes require specific instructions rather than a generic conversion.
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
What is the difference between basal and mealtime insulin?
Basal insulin provides background coverage. Rapid mealtime insulin addresses glucose changes associated with eating.
Are regular insulin and NPH also analogues?
They are insulin preparations, but not modified insulin analogues in the same sense as lispro or glargine.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Insulin analogs (multiple) · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Insulin analogs (multiple) · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.